Topline results from a phase 2 study demonstrated that Allegro Ophthalmics’ first-in-class anti-integrin candidate, Luminate, can help restore vision in diabetic macular edema (DME) patients being treated with anti-VEGF therapy. The drug may also help those with chronic disease who no longer respond to anti-VEGF treatment.
To read the article, please visit American Academy of Ophthalmology: “Novel Integrin Inhibitor May Improve Efficacy Of Anti-VEGF Treatment”
